Medicare insulin cap cut costs, study finds, but gains were uneven

Medicare’s insulin cap appears to be working, but not for everyone

A new study suggests one of the Inflation Reduction Act’s most closely watched drug-pricing changes is delivering measurable benefits for Medicare patients who use insulin. Researchers examining claims data for more than 2.8 million Medicare Part D beneficiaries found that the law’s $35 monthly out-of-pocket cap was associated with lower and more stable insulin costs after taking effect in 2023.

The study, published in JAMA and summarized by Medical Xpress, also found that some patients increased their insulin use after the cap arrived. That matters because insulin affordability is not just a budgeting issue. When patients stretch doses or skip refills because of cost, the medical consequences can be immediate and serious.

Still, the findings point to a more complicated reality than the political slogan around a flat $35 cap might suggest. The biggest benefits were concentrated among a relatively small share of patients who had been paying especially high prices before the policy change. For many other beneficiaries, out-of-pocket costs were already below the cap because they were covered by other subsidy programs or insurance arrangements.

What changed after the cap

The researchers compared insulin spending and usage before and after the policy was implemented. Across the full study population, the out-of-pocket cost for a 30-day insulin supply fell by about $5, or roughly 21%.

That average decline is meaningful, but the broader effect becomes clearer in the subgroup that had faced the highest costs before the rule took effect. Among patients paying at least $58 per 30-day supply before the policy, insulin fills rose by 8%, while the proportion of days covered increased by 5%. In practical terms, the patients under the greatest financial strain were the ones most likely to use more of the medicine once the price pressure eased.

The study also notes that before the cap, some Medicare patients could see their insulin expenses rise sharply during the year. The new structure made those costs more predictable, which may be as important as the headline savings. For patients managing a chronic disease, predictable monthly spending can be the difference between adhering to treatment and falling behind.

Why the effect was limited

The results also show why major policy changes do not always reach every patient in the same way. Medicare Part D beneficiaries are already a relatively well-insured population, and the study found that only 13% of insulin fills in 2021 and 2022 would have exceeded the $35 cap. Many insulin users had already been benefiting from other affordability programs, including Medicare’s Senior Savings Model or the Low-Income Subsidy Program.

That means the new cap did not create an entirely new safety net for the average beneficiary. Instead, it mainly tightened an existing one and prevented the most exposed patients from facing larger spikes in costs.

This is an important distinction for policymakers. A reform can be successful and still have a modest average effect if much of the target population was already partially protected. The study’s findings suggest the cap addressed a real affordability problem, but one concentrated among a minority of users rather than spread evenly across all Medicare insulin patients.

Who benefited most

The patients who saw the greatest benefits were not evenly distributed across the population. According to the study summary, the people helped most by the cap were disproportionately non-Hispanic white, male, between ages 65 and 75, enrolled in fee-for-service insurance, and less likely to live in urban areas.

That pattern raises another policy question: whether a broadly framed affordability measure can still leave important inequities untouched. If the biggest gains flow to groups already better positioned within the health system, then a cost cap may need to be paired with additional strategies to reach patients who face other barriers to care.

Affordability is only one of those barriers. Access to clinicians, transportation, local pharmacy options, plan complexity, and broader income instability can all shape whether a patient stays on therapy. A cap on out-of-pocket spending can reduce one pressure point without solving the entire problem.

What the study suggests next

The researchers argue that the findings support further action on insulin affordability. Medical Xpress cited IQVIA Institute data estimating that a universal $35 cap on all insulin prescriptions in the United States would have saved insulin users $170 million in out-of-pocket costs in 2024.

That estimate points beyond Medicare and toward the larger national pricing debate. The current policy applies to Medicare beneficiaries, but insulin affordability concerns are not limited to that population. Commercially insured patients, uninsured patients, and people with inconsistent coverage can still face significant cost burdens.

The latest evidence does not suggest the Medicare cap solved insulin affordability in full. It does suggest the policy reduced spending and improved use where financial pressure had been most acute. In health policy terms, that is a concrete result: smaller bills, steadier costs, and better adherence for patients who had the most to lose from going without a medicine they depend on every day.

This article is based on reporting by Medical Xpress. Read the original article.